๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9112 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:16 UTC
9112
Studies in scope
industry-sponsored, all four open statuses
4950
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 142 Florida 112 Illinois 101 Arizona 74 Georgia 66
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca230 Eli Lilly and Company150 AbbVie142 Merck Sharp & Dohme LLC130 Novartis Pharmaceuticals113 Clear sponsor filter
State
California142 Florida112 Illinois101 Arizona74 Georgia66
All 46 states
Target enrolment
to

Trials with a site in California

142 of 9112 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 3
520
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
NCT07772492Severe Alopecia Areata
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Nebraska, Ohio, Texas
2026-08-24
Recruiting
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
NCT07071532Bipolar Disorder
AbbVie
Phase 1
20
California, Illinois
2026-08-20
Recruiting
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
NCT07756580Glabellar Lines
AbbVie
Phase 1
120
Arizona, California, Louisiana, Massachusetts, North Carolina, Tennessee, Texas
2026-08-10
Recruiting
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
NCT07752979Obesity, Overweight
AbbVie
Phase 2
360
Alabama, Arizona, California, Florida, Idaho, Illinois, Kentucky, Missouri
2026-08-04
Recruiting
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456Crohn's Disease, Ulcerative Colitis
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
Recruiting
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants
NCT07736638Healthy Volunteer
AbbVie
Phase 1
64
California, Illinois
2026-07-28
Recruiting
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants
NCT07730554Forehead Lines
AbbVie
Phase 2
80
California, New York, North Carolina, Texas
2026-07-22
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002Acute Myeloid Leukemia
AbbVie
Phase 2/3
660
California, Florida, Georgia, Missouri, New York, Texas
2026-06-30
Recruiting
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
NCT07673107Upper Limb Essential Tremor
AbbVie
Phase 2
94
California, Florida
2026-06-18
Recruiting
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
NCT07466550Healthy Volunteer
AbbVie
Phase 1
60
California, Florida
2026-06-04
Recruiting
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
NCT07592273Diabetic Retinopathy
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07607964Systemic Lupus Erythematosus, Rheumatoid Arthritis
AbbVie
Phase 1
30
Alabama, California, Florida, Illinois, Texas
2026-05-28
Active, closed
A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants
NCT07604558Healthy Volunteer
AbbVie
Phase 1
26
California
2026-05-26
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
AbbVie
Phase 3
990
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-05-22
Recruiting
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832Acute Myeloid Leukemia
AbbVie
Phase 1
18
California, New York, Tennessee, Texas
2026-05-20
Recruiting
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670Alzheimer's Disease
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Active, closed
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
NCT07514260Healthy Volunteer
AbbVie
Phase 1
24
California
2026-03-31
Recruiting
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
NCT07409246Multiple Myeloma
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Michigan
2026-02-27
Recruiting
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
NCT07226791Ventral Hernia
AbbVie
Phase 2
200
California, Florida, Illinois, Kansas, Minnesota, North Carolina, Ohio, Pennsylvania
2026-02-04
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
NCT06696755Bipolar I Disorder, Bipolar II Disorder
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-02-03
Recruiting
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
NCT07310290Migraine
AbbVie
Observational
189
California, Illinois, Nebraska
2026-01-27
Recruiting
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452Multiple Myeloma
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
NCT07276997Major Depressive Disorder
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada
2025-12-18
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
AbbVie
Phase 2/3
490
Arkansas, California, Florida, Indiana, Minnesota, Nebraska, New Hampshire, New Jersey
2025-12-10
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644Solid Tumors Harboring MET Amplification
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Active, closed
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
NCT07232004Healthy Volunteer
AbbVie
Phase 1
121
Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri
2025-11-24
Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRฮฑ)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT06890338Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
AbbVie
Phase 2
140
Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana
2025-11-21
Recruiting
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039Advanced Squamous Tumors
AbbVie
Phase 1
220
California, Illinois, Michigan, North Carolina, Texas
2025-11-20
Recruiting
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
NCT07291232Obesity
AbbVie
Phase 1
80
California, Illinois
2025-11-19
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845Ovarian Cancer
AbbVie
Phase 2
400
California, Florida, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Montana
2025-11-13
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Recruiting
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
NCT07207369Acne Scars
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
NCT07219030Healthy Volunteer
AbbVie
Phase 1
52
California, Florida, Illinois, New Jersey
2025-10-08
Recruiting
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
NCT07220460Bipolar I or II Disorder
AbbVie
Phase 2
200
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2025-09-30
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289Colorectal Cancer
AbbVie
Phase 2
140
Alabama, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-09-02
Recruiting
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06896916Multiple Myeloma
AbbVie
Phase 1
135
California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington
2025-08-07
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918Schizophrenia
AbbVie
Phase 2
268
Arkansas, California, Maryland, New Jersey, Texas
2025-08-04
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3
854
Arizona, California, Colorado, Florida, Hawaii, Iowa, Nebraska, Nevada
2025-08-03
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
AbbVie
Phase 3
120
Arizona, California, Florida, Georgia, Illinois, New Jersey, Ohio, Pennsylvania
2025-07-28
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
NCT06892522Multiple Myeloma
AbbVie
Phase 1/2
602
California, Colorado, Florida, Georgia, New York, North Carolina, Ohio, Texas
2025-06-30
Recruiting
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446Rheumatoid Arthritis
AbbVie
Phase 2
180
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Michigan
2025-06-20
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-17
Recruiting
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320Generalized Anxiety Disorder (GAD)
AbbVie
Phase 2
315
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-04-29
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
AbbVie
Phase 2
390
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2025-04-24
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
NCT06858813Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
AbbVie
Phase 1
232
California, Illinois, Missouri, New York, Pennsylvania, Tennessee
2025-04-14
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105Psoriatic Arthritis
AbbVie
Phase 2
120
California, Florida, Illinois, Maryland, Ohio, Pennsylvania, Tennessee, Texas
2025-04-11
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
NCT06895343Healthy Volunteer
AbbVie
Phase 1
100
California, Illinois
2025-04-03
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
AbbVie
Phase 1/2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Massachusetts
2025-03-06
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505Chronic Migraine
AbbVie
Phase 3
420
Alabama, Arkansas, California, Florida, Indiana, Michigan, Mississippi, Nebraska
2025-02-13
Recruiting
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
NCT06822738Primary Open Angle Glaucoma
AbbVie
Phase 3
130
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2025-02-11
Active, closed
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
AbbVie
Phase 1
4
California, Montana, North Carolina, Texas
2025-01-27
Recruiting
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939Non-Small Cell Lung Cancer
AbbVie
Phase 2
150
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-01-20
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
NCT06632951Urothelial Carcinoma
AbbVie
Phase 2
150
Arkansas, California, Connecticut, Delaware, Florida, New York, Ohio, Tennessee
2025-01-20
Active, closed
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101Atopic Dermatitis
AbbVie
Phase 2
83
Arizona, California, Colorado, Florida, Illinois, Nebraska, New York, Oregon
2024-12-19
Recruiting
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVร‰DERM VOLUMA XC for Improvement of Mid-Face Volume
NCT06734351Mid Face Volume Deficit
AbbVie
Phase 3
231
Alabama, Arizona, California, Florida, Georgia, Louisiana, Maryland, New York
2024-12-16
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
AbbVie
Phase 2
185
California, Florida, Georgia, Mississippi, North Carolina, Texas
2024-12-13
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Alabama, Arizona, California, Florida, Kentucky, New York, Pennsylvania, Virginia
2024-11-26
Active, closed
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192Metastatic Colorectal Cancer
AbbVie
Phase 3
74
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-11-08
Recruiting
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192Breast Reconstruction
AbbVie
Phase 3
264
California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey
2024-11-05
Recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479Migraine
AbbVie
Phase 2
488
Alabama, California, Florida, Kentucky, New York, Rhode Island, South Carolina, Texas
2024-10-07
Active, closed
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775Migraine
AbbVie
Phase 3
496
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii
2024-09-10
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
AbbVie
Phase 2
540
Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2024-09-04
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
AbbVie
Phase 3
675
Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky
2024-08-19
Recruiting
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
NCT06524635Hidradenitis Suppurativa, Atopic Dermatitis
AbbVie
Phase 2
60
California, Michigan
2024-08-14
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
AbbVie
Phase 3
110
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019Chronic Lymphocytic Leukemia
AbbVie
Phase 3
170
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa
2024-08-05
Active, closed
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
AbbVie
Phase 2
108
California, Kentucky, Maryland, Missouri, Nevada, New Jersey, New York, North Carolina
2024-07-29
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
AbbVie
Phase 3
1,400
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-27
Recruiting
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136Atopic Dermatitis
AbbVie
Phase 3
200
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-14
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana
2024-05-19
Recruiting
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339Hypothyroidism
AbbVie
Phase 2/3
2,800
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2024-04-26
Recruiting
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06236438Non-Small Cell Lung Cancer
AbbVie
Phase 2/3
840
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-04-10
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875Ulcerative Colitis
AbbVie
Phase 2
156
California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2024-03-23
Active, closed
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06318273Metastatic Castration-Resistant Prostate Cancer
AbbVie
Phase 1
152
California, Connecticut, Florida, Illinois, Michigan, North Carolina, Rhode Island, Texas
2024-03-08
Active, closed
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
NCT06107426Parkinson's Disease (PD)
AbbVie
Observational
427
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Louisiana, Massachusetts
2024-01-24
Active, closed
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06109272Hepatocellular Carcinoma
AbbVie
Phase 2/3
89
California, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, Texas
2024-01-11
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
AbbVie
Phase 3
614
Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2023-12-19
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Arizona, Arkansas, California, Colorado, Florida, Indiana, Massachusetts, Minnesota
2023-12-11
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2023-11-15
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT06107413Unresectable Metastatic Colorectal Cancer
AbbVie
Phase 2
280
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Louisiana
2023-11-12
Recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
AbbVie
Phase 1
325
California, Colorado, Florida, Illinois, Michigan, Missouri, New York, North Carolina
2023-11-09
Active, closed
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907Ulcerative Colitis
AbbVie
Phase 3
122
Arizona, Arkansas, California, Colorado, Delaware, Georgia, Illinois, Massachusetts
2023-11-06
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
AbbVie
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-10-11
Active, closed
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT05822752Hepatocellular Carcinoma
AbbVie
Phase 2
130
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Massachusetts
2023-09-21
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-25
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
AbbVie
Phase 3
1,328
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2023-06-21
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
AbbVie
Phase 1
135
Arizona, California, Colorado, Illinois, Massachusetts, New Jersey, New York, Ohio
2023-06-09
By invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949Migraine Prophylaxis
AbbVie
Phase 3
650
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-06-05
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394Episodic Migraine
AbbVie
Phase 3
450
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-05-01
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
California, Connecticut, Florida, Indiana, Louisiana, Michigan, New York, North Carolina
2023-04-04
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa
2023-03-15
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
AbbVie
Phase 1
256
Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Mississippi
2023-01-11
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
AbbVie
Phase 1
288
Arizona, California, Connecticut, District of Columbia, Illinois, Indiana, Iowa, Michigan
2022-12-05
Active, closed
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRฮฑ) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 2
125
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts
2022-09-28
Active, closed
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
NCT05308654Relapsed/Refractory Multiple Myeloma
AbbVie
Phase 1
34
California, Florida, Louisiana, Maryland, Michigan, Minnesota, New York, North Carolina
2022-05-17
By invitation
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
NCT05296447Diabetic Retinopathy, DR
AbbVie
Phase 2
100
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Jersey
2022-04-04
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 2
75
California, Georgia, Iowa, Massachusetts, Michigan, Minnesota, Mississippi, New Jersey
2022-03-28
Rows per page Showing 1–100 of 142
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,112 studies in total at the last sync on 23 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 142 of those studies with a site in California that also match the filters currently applied.

How many clinical trials are recruiting in California?

68 of the 142 studies on this page are recruiting new participants as of the 23 Sep 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 67 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (California), 142 studies
PhaseStudiesRecruitingShare
Phase 3512035.9%
Phase 2372226.1%
Phase 1321422.5%
Phase 2/3976.3%
Phase 1/2845.6%
Observational513.5%

Most active sponsors

Lead sponsors with the most studies (California)
Lead sponsorStudiesRecruiting
AbbVie14268
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.